Skip to main content
MedPathMedPath Home
Clinical Trials/NCT02720770
NCT02720770
Completed
Phase 1

Proposition Pour un Traitement Par Hormone de Croissance Des Enfants Atteints de Rachitisme Hypophosphatemique Familial

Bicetre Hospital0 sites19 target enrollmentJanuary 2006
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsX Linked Hypophosphatemic Rickets
Interventionsnorditropine simplex
Drugsnorditropine simplex

Overview

Phase
Phase 1
Intervention
norditropine simplex
Conditions
X Linked Hypophosphatemic Rickets
Sponsor
Bicetre Hospital
Enrollment
19
Primary Endpoint
change from baseline in height SDS (standard deviation score)
Status
Completed
Last Updated
10 years ago
OverviewInvestigatorsEligibility CriteriaArms & InterventionsOutcomesSimilar Trials

Overview

Brief Summary

This study evaluates the effect on height of a two year treatment with growth hormone in 19 children with X linked hypophosphatemic rickets.

Registry
clinicaltrials.gov
Start Date
January 2006
End Date
January 2011
Last Updated
10 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Bicetre Hospital
Responsible Party
Principal Investigator
Principal Investigator

Alessia Usardi

Professor

Bicetre Hospital

Eligibility Criteria

Inclusion Criteria

  • •clinical, biochemical and genetic diagnosis of XLH
  • •height SDS \< 2
  • •at least two years of treatment with oral phosphate and calcitriol

Exclusion Criteria

  • •uncontrolled rickets (ALP\>600 IU)
  • •growth hormone deficiency
  • •hyperparathyroidism, nephrocalcinosis, renal insufficiency
  • •associated disease
  • •previous treatment with growth hormone

Arms & Interventions

norditropine simplex

Intervention: norditropine simplex

Outcomes

Primary Outcomes

change from baseline in height SDS (standard deviation score)

Time Frame: at year one and year two from baseline

Similar Trials

Completed
Phase 2
Phase II Study of Growth Hormone in Children With Cystic FibrosisCystic Fibrosis
NCT00016445University of Utah40
Completed
Phase 3
Genotropin Treatment In Very Young Children Born Small For Gestational AgeInfant, Small for Gestational Age
NCT00627523Pfizer43
Terminated
Phase 4
Study of Growth-promoting and Metabolic Effects of Growth Hormone (rhGH)Small for Gestational Age
NCT00597480Assistance Publique - Hôpitaux de Paris10
Completed
Phase 2
Growth Response in Short Children Suffering From a Disease With Growth Retardation and Treated With SomatropinIdiopathic Short Stature
NCT00488124University of Erlangen-Nürnberg Medical School120
Terminated
Phase 2
Three Month Treatment of Growth Hormone Releasing Hormone (GHRH) in the ElderlyHormone DeficiencyAging
NCT01410799University of Pennsylvania13